OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

OraSure Technologies, Inc.

Boston Scientific (BSX) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $0.56 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 11.94%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $0.65 per share when it actually produced earnings of $0.70, delivering a surprise of 7.69%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Boston Scientific, which belongs to the Zacks Medical - Products industry, posted revenues of $4.66 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.31%. This compares to year-ago revenues of $3.86 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Boston Scientific shares have added about 6.4% since the beginning of the year versus the S&P 500's decline of -10.1%.
What's Next for Boston Scientific?
While Boston Scientific has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Boston Scientific: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.71 on $4.78 billion in revenues for the coming quarter and $2.85 on $19.13 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, OraSure Technologies (OSUR), has yet to report results for the quarter ended March 2025.
This diagnostic test maker is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of -475%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
OraSure Technologies' revenues are expected to be $29.72 million, down 45.1% from the year-ago quarter.
Should You Invest in Boston Scientific Corporation (BSX)?
Before you invest in Boston Scientific Corporation (BSX), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
OraSure Technologies, Inc. (OSUR) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Boston Scientific (BSX) Q1 Earnings and Revenues Top Estimates

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins.
ORASURE TECHNOLOGIES INC (OSUR) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Kenneth Fisher changed from 50% to 70% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: OraSure Technologies, Inc. provides point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services. The Company's product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. Its business also includes molecular sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of ORASURE TECHNOLOGIES INC
OSUR Guru Analysis
OSUR Fundamental Analysis
MERCK KGAA (ADR) (MKKGY) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Kenneth Fisher changed from 28% to 80% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Electronics. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The Life Sciences business comprises the activities of MilliporeSigma, which provides solutions that facilitate biotechnology and pharmaceutical research. The product range includes laboratory water systems, gene editing tools, cell lines and end-to-end drug manufacturing systems, among others. The Electronics business enables digital living and provides specialty chemicals for various applications, including liquid crystals for electronic displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of MERCK KGAA (ADR)
MKKGY Guru Analysis
MKKGY Fundamental Analysis
Kenneth Fisher Portfolio
About Kenneth Fisher: The son of Philip Fisher, who is considered the "Father of Growth Investing", Kenneth Fisher is a money manager, bestselling author, and longtime Forbes columnist. The younger Fisher wowed Wall Street in the mid-1980s when his book Super Stocks first popularized the idea of using the price/sales ratio (PSR) as a means of identifying attractive stocks. According to his alma mater, Humboldt State University, Fisher is also one of the world's foremost experts on 19th century logging. Appropriately, Fisher's firm, Fisher Investments, is located in a lush forest preserve in Woodside, California, where the contrarian-minded Fisher says he and his employees can get away from Wall Street groupthink.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Validea Kenneth Fisher Strategy Daily Upgrade Report - 3/12/2025

Insulet (PODD) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.40 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 9.52%. A quarter ago, it was expected that this maker of insulin infusion systems would post earnings of $0.77 per share when it actually produced earnings of $0.90, delivering a surprise of 16.88%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Insulet, which belongs to the Zacks Medical - Products industry, posted revenues of $597.5 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 2.73%. This compares to year-ago revenues of $509.8 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Insulet shares have added about 8.7% since the beginning of the year versus the S&P 500's gain of 4.5%.
What's Next for Insulet?
While Insulet has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Insulet: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.79 on $538.9 million in revenues for the coming quarter and $3.92 on $2.42 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the top 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, OraSure Technologies (OSUR), has yet to report results for the quarter ended December 2024. The results are expected to be released on February 25.
This diagnostic test maker is expected to post quarterly loss of $0.02 per share in its upcoming report, which represents a year-over-year change of -109.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
OraSure Technologies' revenues are expected to be $36.62 million, down 51.8% from the year-ago quarter.
Should You Invest in Insulet Corporation (PODD)?
Before you invest in Insulet Corporation (PODD), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Insulet Corporation (PODD) : Free Stock Analysis Report
OraSure Technologies, Inc. (OSUR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Insulet (PODD) Q4 Earnings and Revenues Top Estimates

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
Alnylam Pharmaceuticals, Inc. ALNY: This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 15.2% over the last 60 days.
Alnylam Pharmaceuticals, Inc. Price and Consensus
Alnylam Pharmaceuticals, Inc. price-consensus-chart | Alnylam Pharmaceuticals, Inc. Quote
HBT Financial, Inc. HBT: This bank holding company has seen the Zacks Consensus Estimate for its current year earnings increasing 8.8% over the last 60 days.
HBT Financial, Inc. Price and Consensus
HBT Financial, Inc. price-consensus-chart | HBT Financial, Inc. Quote
Amphenol Corporation APH: This electrical and electronics manufacturing company has seen the Zacks Consensus Estimate for its current year earnings increasing 5.1% over the last 60 days.
Amphenol Corporation Price and Consensus
Amphenol Corporation price-consensus-chart | Amphenol Corporation Quote
Guaranty Bancshares, Inc. GNTY: This bank holding company has seen the Zacks Consensus Estimate for its current year earnings increasing 16.5% over the last 60 days.
Guaranty Bancshares Inc. Price and Consensus
Guaranty Bancshares Inc. price-consensus-chart | Guaranty Bancshares Inc. Quote
OraSure Technologies, Inc. OSUR: This manufacturer and seller of oral fluid diagnostic products has seen the Zacks Consensus Estimate for its current year earnings increasing 14.3% over the last 60 days.
OraSure Technologies, Inc. Price and Consensus
OraSure Technologies, Inc. price-consensus-chart | OraSure Technologies, Inc. Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report
Amphenol Corporation (APH) : Free Stock Analysis Report
OraSure Technologies, Inc. (OSUR) : Free Stock Analysis Report
Guaranty Bancshares Inc. (GNTY) : Free Stock Analysis Report
HBT Financial, Inc. (HBT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

New Strong Buy Stocks for January 27th

Insulet (PODD) came out with quarterly earnings of $1.40 per share, beating the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 108.96%. A quarter ago, it was expected that this maker of insulin infusion systems would post earnings of $0.40 per share when it actually produced earnings of $0.71, delivering a surprise of 77.50%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Insulet, which belongs to the Zacks Medical - Products industry, posted revenues of $509.8 million for the quarter ended December 2023, surpassing the Zacks Consensus Estimate by 10.79%. This compares to year-ago revenues of $369.7 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Insulet shares have lost about 11.3% since the beginning of the year versus the S&P 500's gain of 4.4%.
What's Next for Insulet?
While Insulet has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Insulet: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.45 on $439.21 million in revenues for the coming quarter and $2.54 on $1.97 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, OraSure Technologies (OSUR), is yet to report results for the quarter ended December 2023. The results are expected to be released on February 27.
This diagnostic test maker is expected to post quarterly earnings of $0.13 per share in its upcoming report, which represents a year-over-year change of -38.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
OraSure Technologies' revenues are expected to be $74.57 million, down 39.4% from the year-ago quarter.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Insulet (PODD) Surpasses Q4 Earnings and Revenue Estimates

Baxter International (BAX) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.88 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 2.33%. A quarter ago, it was expected that this drug and medical device maker would post earnings of $0.66 per share when it actually produced earnings of $0.68, delivering a surprise of 3.03%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Baxter, which belongs to the Zacks Medical - Products industry, posted revenues of $3.89 billion for the quarter ended December 2023, surpassing the Zacks Consensus Estimate by 2.28%. This compares to year-ago revenues of $3.89 billion. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Baxter shares have added about 1.9% since the beginning of the year versus the S&P 500's gain of 4.7%.
What's Next for Baxter?
While Baxter has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Baxter: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.63 on $3.61 billion in revenues for the coming quarter and $2.93 on $15.19 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, OraSure Technologies (OSUR), is yet to report results for the quarter ended December 2023.
This diagnostic test maker is expected to post quarterly earnings of $0.13 per share in its upcoming report, which represents a year-over-year change of -38.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
OraSure Technologies' revenues are expected to be $74.57 million, down 39.4% from the year-ago quarter.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Baxter International (BAX) Tops Q4 Earnings and Revenue Estimates

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins.
RAMACO RESOURCES INC (METC) is a small-cap value stock in the Coal industry. The rating according to our strategy based on Kenneth Fisher changed from 68% to 90% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ramaco Resources, Inc. is a metallurgical coal company. The Company operates and develops metallurgical coal in southern West Virginia, southwestern Virginia, and southwestern Pennsylvania. The Company's development portfolio primarily includes four properties: Elk Creek, Berwind, Knox Creek and RAM Mine. The Elk Creek property consists of approximately 20,200 acres of controlled mineral rights and contains approximately 16 seams that it has targeted for production. Its operations include approximately six active mines at its Elk Creek mining complex. The Berwind property consists of approximately 62,500 acres of controlled mineral and is located on the border of West Virginia and Virginia. The Company's Knox Creek facility includes a preparation plant and approximately 74,400 acres of controlled mineral rights. Its RAM Mine property is located in southwestern Pennsylvania, consists of approximately 1,567 acres of controlled mineral rights.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of RAMACO RESOURCES INC
ORASURE TECHNOLOGIES, INC. (OSUR) is a small-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Kenneth Fisher changed from 40% to 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: OraSure Technologies, Inc. is engaged in the development and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions. The Company operates through two segments: the Diagnostics segment and the Molecular Solutions segment. The Diagnostics business primarily consists of the development, manufacture, marketing, and sale of simple, easy-to-use diagnostic products and specimen collection devices using its proprietary technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Molecular Solutions business is operated by Company's subsidiaries, DNA Genotek, Diversigen, and Novosanis. The Molecular Solutions segment products primarily consist of collection kits and services used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of ORASURE TECHNOLOGIES, INC.
About Kenneth Fisher: The son of Philip Fisher, who is considered the "Father of Growth Investing", Kenneth Fisher is a money manager, bestselling author, and longtime Forbes columnist. The younger Fisher wowed Wall Street in the mid-1980s when his book Super Stocks first popularized the idea of using the price/sales ratio (PSR) as a means of identifying attractive stocks. According to his alma mater, Humboldt State University, Fisher is also one of the world's foremost experts on 19th century logging. Appropriately, Fisher's firm, Fisher Investments, is located in a lush forest preserve in Woodside, California, where the contrarian-minded Fisher says he and his employees can get away from Wall Street groupthink.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Validea Kenneth Fisher Strategy Daily Upgrade Report - 2/1/2024

For Immediate Release
Chicago, IL – January 19, 2024 – Stocks in this week’s article are Otter Tail Corp. OTTR, OraSure Technologies Inc. OSUR, BioMarin Pharmaceutical Inc. BMRN and Regeneron Pharmaceuticals, Inc. REGN.
Buy These 4 Low-Beta Stocks to Counter Market Volatility
The "fear gauge" on Wall Street has reached a two-month high due to a decline in U.S. stocks. However, encouraging retail sales highlights the economy’s strength. Overall, the market is likely to maintain its volatility, emphasizing the immediate necessity of constructing a portfolio comprising low-beta stocks. These securities are anticipated to generate substantial returns while offering a protective shield against unpredictable market conditions.
In this regard, stocks like Otter Tail Corp., OraSure Technologies Inc., BioMarin Pharmaceutical Inc. and Regeneron Pharmaceuticals, Inc. are worth betting on.
Understanding Beta
Beta measures the volatility or risk of a particular asset compared to the market. In other words, beta measures the extent of a security’s price movement relative to the market. In this article, we are considering the S&P 500 as the market.
If a stock has a beta of 1, then the price of the stock will move with the market. So, the stock is more volatile than the market if its beta is more than 1. In the same way, the stock is not as volatile as the market if its beta is less than 1.
For example, if the market offers a return of 20%, a stock with a beta of 3 will return 60%, which is overwhelming. Similarly, when the market slips 20%, the stock will sink 60%, which is devastating.
Here are four of the 11 stocks that qualified the screening:
Otter Tail Corporation is a leading player in electric utility and manufacturing businesses. Recovery of rate base investments continues to drive the firm. For 2024, Otter Tail has witnessed upward earnings estimate revisions in the past 60 days.
OraSure Technologies is a leading provider of specimen collection devices, point-of-care and home diagnostic tests. OraSure is focused on key strategic partnerships and internal innovation. OSUR has witnessed upward estimate revisions for its bottom line for 2024 over the past 60 days.
BioMarin Pharmaceutical, a prominent player in the field of biotechnology, specializes in the development of targeted therapies aimed at addressing the underlying causes of genetic conditions. FDA approval for VOXZOGO is a huge success for the company, which, along with other notable developments, will aid the top line.
Regeneron Pharmaceuticals is a prominent biotechnology company. With a robust business model, it engages in the discovery, development and commercialization of life-changing medications. The company is involved in improving its traditional drug development process.
You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial to the Research Wizard today.
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2211917/buy-these-4-low-beta-stocks-to-counter-market-volatility
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Visit: https://www.zacks.com/
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

OraSure Technologies, Inc.

Sign up and unlock all the capabilities of the AI-screener